Tratamento de prevenção secundária
DOI:
https://doi.org/10.25118/2763-9037.2011.v1.1430Palavras-chave:
transtorno bipolar, prevenção, litio, antipsicótico, quetiapinaResumo
.
Downloads
Métricas
Referências
• 1 Gus I. Prevenção da Cardiopatia Isquêmica. O Inves-timento na Saúde. Arq Bras Cardiol 1998; 70(5). DOI: https://doi.org/10.1590/S0066-782X1998000500009
• 2 Fakra E, Kaladjian A, Da Fonseca D, Maurel M, Adida M, Besnier N, Pringuey D, Azorin J-M. Phase prodro-male du trouble bipolaire. Encephale 2010; 36: 8-12. DOI: https://doi.org/10.1016/S0013-7006(10)70003-8
• 3 American Psychiatric Association. DSM-IV-TR2000. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washigton, DC: American Psychiatric Association, 2000. Text Revision
• 4 Hauser M, Pfennig A, Ozgurdal S, Heinz A, Bauer M, Juckel G. Early recognition of bipolar disorder. Eur Psychiatry 2007; 22: 92-98. DOI: https://doi.org/10.1016/j.eurpsy.2006.08.003
• 5 Berk M, Malhi GS, Hallam K, Gama CS, Dodd S, An-dreazza AC,Frey BN, Kapczinski F. Early intervention in bipolar disorders: clinical, biochemical and neuroima-ging imperatives. J Affect Disord 2009; 114: 1-13. DOI: https://doi.org/10.1016/j.jad.2008.08.011
• 6 American Psychiatric Association. Practice guideli-nes for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50.
• 7 Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME. Predictors of recurrence in bipolar di-sorder: primary outcomes from the Systematic Tre-atment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006; 163: 217-224. DOI: https://doi.org/10.1176/appi.ajp.163.2.217
• 8 Conus P, Ward J, Hallam KT, Lucas N, Macneil C, McGorry PD. Symptomatic and funtional outcome 12 months after a first episode of psychot mania: barriers to recovery in a catchment área sample. Bipolar Disord 2006; 8(3): 221-31. DOI: https://doi.org/10.1111/j.1399-5618.2006.00315.x
• 9 Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beau-lieu S, O’Donovan C, MacQueen G, McIntyre RS, Shar-ma V, Ravindran A, Young LT, Young AH, Alda M, Mi-lev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Di-sorders (ISBD) collaborative update of CANMAT gui-delines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 11: 225-255. DOI: https://doi.org/10.1111/j.1399-5618.2009.00672.x
• 10 Ghaemi SN, Boiman EE, Goodwin FK. Kindling and second messengers:an approach to the neurobiology of recurrence in bipolar disorder. Biol Psychiatry. 1999; 45(2): 137-4 4. DOI: https://doi.org/10.1016/S0006-3223(98)00256-X
• 11 Kessing LV, Hansen MG, Andersen PK, Angst J. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders—a life-long pers-pective. Acta Psychiatr Scand 2004; 109: 339-344. DOI: https://doi.org/10.1046/j.1600-0447.2003.00266.x
• 12 Berk M, Brnabic A, Dodd S et al. Does stage of ill-ness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord 2011; 13(1): 87-98. DOI: https://doi.org/10.1111/j.1399-5618.2011.00889.x
• 13 Farrow TFD, Whitford TJ, Williams LM et al. Diag-nosis-related regional gray matter loss over two years in first episode schizophrenia and bipolar disorder. Biol Psychiatry 2005; 58: 713-723. DOI: https://doi.org/10.1016/j.biopsych.2005.04.033
• 14 Frazier JA, Breeze JL, Makris N et al. Cortical gray matter differences identified by structural magnetic resonance imaging in pediatric bipolar disorder. Bipo-lar Disord 2005; 7: 555-569. DOI: https://doi.org/10.1111/j.1399-5618.2005.00258.x
• 15 Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 1999; 46(7): 929-940. DOI: https://doi.org/10.1016/S0006-3223(99)00165-1
• 16 Chuang DM, Chen RW, Chalecka-Franaszek E et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002; 4(2): 129-136 . DOI: https://doi.org/10.1034/j.1399-5618.2002.01179.x
• 17 Kapczinski F, Dal-Pizzol F, Teixeira AL et al. Periphe-ral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2010; Jun 10. [Epub ahead of print]
• 18 Moore GJ, Cortese BM, Glitz DA et al. A longitudi-nal study of the effects of lithium treatment on pre-frontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 2009; 70(5): 699-705. DOI: https://doi.org/10.4088/JCP.07m03745
• 19 Martinez-Aran A, Scott J, Colom F et al. Treatment nonadherence and neurocognitive impairment in bi-polar disorder. J Clin Psychiatry 2009; 70(7): 1017-1023. DOI: https://doi.org/10.4088/JCP.08m04408
• 20 Popovic D, Reinares M, Amann B, Salamero M, Vieta E. Nunber needed to treat analyses of drugs for maintenance treatment of bipolar disorder. Psycho-pharmacology 2011 213: 657-667. DOI: https://doi.org/10.1007/s00213-010-2056-8
• 21 Bowden CL, Calabrese JR, Sachs G, Yatham LN, As-ghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh- Geiss J, Lamictal. A placebo-controlled 18-month trial of lamotrigine and lithium maintenan-ce treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-40 0.
• 22 Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R. A pooled analysis of 2 placebocontrolled 18-month trials of la-motrigine and lithium maintenance in bipolar I disor-der. J Clin Psychiatry 2004; 65: 432-441. DOI: https://doi.org/10.4088/JCP.v65n0321
• 23 Nolen WA, Weisler RH, Neijber A, Hellqvist A, Paulsson B. Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after sta-bilization on quetiapine. Presented at the 17th Euro-pean Congress of Psychiatry, Lisbon, Portugal, 24-25 January, 2009. DOI: https://doi.org/10.1016/S0924-9338(09)70828-4
• 24 Malhi GS, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression phar-macotherapy. Bipolar Disord 2009; 11: 55-76. DOI: https://doi.org/10.1111/j.1399-5618.2009.00711.x
• 25 Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wa-ssef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, Swann AC,Hirschfeld RM, Wozniak PJ. A randomi-zed, placebocontrolled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57: 481-489. DOI: https://doi.org/10.1001/archpsyc.57.5.481
• 26 Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar de-pression. Neuropsychopharmacology 2003; 28: 1374-1382. DOI: https://doi.org/10.1038/sj.npp.1300190
• 27 Bowden CL. Anticonvulsants in bipolar disorder: current research and practice and future directions. Bipolar Disord 2009; 11: 20-33. DOI: https://doi.org/10.1111/j.1399-5618.2009.00708.x
• 28 Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR. Pharmacological interventions for the pre-vention of relapse in bipolar disorder: a systematic re-view of controlled trials. J Psychopharmacol 2009; 23: 574 -91. DOI: https://doi.org/10.1177/0269881108093885
• 29 Bowden CL, Calabrese JR, Sachs G, Yatham LN, As-ghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh- Geiss J, Lamictal. A placebo-controlled 18-month trial of lamotrigine and lithium maintenan-ce treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400. DOI: https://doi.org/10.1001/archpsyc.60.4.392
• 30 Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J, Lamictal. A pla-cebocontrolled 18-month trial of lamotrigine and li-thium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024. DOI: https://doi.org/10.4088/JCP.v64n0906
• 31 Fountolakis KN, Vieta E. Treatment of bipolar disor-der: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008; 11: 999-1029. DOI: https://doi.org/10.1017/S1461145708009231
• 32 Ceron-Litvoc D, Soares BG, Geddes J, Litvoc J, de Lima MS. Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials. Hum Psychopharmachol 2009; 24: 19-28. DOI: https://doi.org/10.1002/hup.990
• 33 Narasimhan M, Bruce TO, Masand P. Review of olanzapine in the management of bipolar disorders. Neuropsychiatric Disease and Teatment 2007; 3: 579-5 87.
• 34 Rosa AR, Andreazza AC, Kunz M, Gomes F, Santin A, Sanchez-Moreno J, Reinares M, Colom F, Vieta E, Kapczinski F. Predominant polarity in bipolar disorder: Diagnostic implications. Journal of Affective Disorders 2008; 107: 45-51. DOI: https://doi.org/10.1016/j.jad.2007.07.021
• 35 Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL. Rando-mized, placebo-controlled trial of olanzapine as main-tenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Ame-rican Journal of Psychiatry 2006; 163: 247-256. DOI: https://doi.org/10.1176/appi.ajp.163.2.247
• 36 Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled cli-nical trial. American Journal of Psychiatry 2005; 162: 1281-1290. DOI: https://doi.org/10.1176/appi.ajp.162.7.1281
• 37 Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combi-nation with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-263. DOI: https://doi.org/10.1016/j.jad.2008.06.001
• 38 Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I di-sorder: results from a North American study of quetia-pine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166: 476-488. DOI: https://doi.org/10.1176/appi.ajp.2008.08020189
• 39 Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting in-jectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68: 156-162. DOI: https://doi.org/10.1016/j.biopsych.2010.01.015
• 40 Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, Kujawa M, Mahmoud R. A randomized, double-blind, placebo-controlled study of maintenan-ce treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009; 11: 827-839. DOI: https://doi.org/10.1111/j.1399-5618.2009.00761.x
• 41 Kemp DE, Canan F, Goldstein BI, McIntyre RS. Long--acting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther 2009; 26: 588-599. DOI: https://doi.org/10.1007/s12325-009-0039-0
• 42 Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R. Aripiprazole monotherapy for maintenan-ce therapy in bipolar I disorder: a 100-week, double--blind study versus placebo. J Clin Psychiatry 2007; 68: 1480-1491. DOI: https://doi.org/10.4088/JCP.v68n1003
• 43 Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH. Aripipra-zole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009; 112: 36-49.por gISELE SERpA, FABIAnA nERy-FERnAnDES e ÂngELA MIRAnDA-SCIppA DOI: https://doi.org/10.1016/j.jad.2008.05.014
• 44 Yatham LN. A clinical review of aripiprazol in bi-polar depression and maintenance therapy for bipolar disorder. J Affect Disord 2011; 128: 21-28. DOI: https://doi.org/10.1016/S0165-0327(11)70005-2
• 45 Marcus R, Khan A, Rollin L, Morris B, Timko K, Car-son W, Sanchez R. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate res-ponse to lithium or valproate monotherapy: a multi-center, double-blind, randomized study. Bipolar Disord 2011; 13: 133-14 4. DOI: https://doi.org/10.1111/j.1399-5618.2011.00898.x
• 46 Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in sub-jects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010 ; 71: 130 -137. DOI: https://doi.org/10.4088/JCP.09m05482yel
• 47 Citrome L. Ziprasidone HCl capsules for the ad-junctive maintenance treatment of bipolar disorder in adults. Expert Rev Neurother. 2010;10(7): 1031-1037. DOI: https://doi.org/10.1586/ern.10.66
• 48 Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. American Journal of Psychiatry 1999; 156: 1164-1169. DOI: https://doi.org/10.1176/ajp.156.8.1164
• 49 Vieta E, Cruz N, García-Campayo J, de Arce R, Ma-nuel Crespo J, Vallès V, Pérez-Blanco J, Roca E, Manuel Olivares J, Moríñigo A, Fernández-Villamor R, Comes M. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treat-ment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008; 11: 445-452. DOI: https://doi.org/10.1017/S1461145708008596
• 50 Schaffer CB, Schaffer LC, Miller AR, Hang E, Nordahl TE. Efficacy and safety of nonbenzodiazepine hypno-tics for chronic insomnia in patients with bipolar disor-der. J Affect Disord 2011; 128: 305-308. DOI: https://doi.org/10.1016/j.jad.2010.07.018
• 51 Frye MA. Bipolar disorder – a focus on depression. The New England Journal of Medicine 2011; 364: 51-59. DOI: https://doi.org/10.1056/NEJMcp1000402
• 52 Suppes T, Kelly D. Update of the Texas Implemen-tation of Medication Algorithms for Bipolar I Disorder. Medscape Psychiatry & Mental Health 2006; 11 (1).
• 53 Grunze H, Kasper S, Goodwin G, Bowden C, Mol-ler HJ. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treat-ment of bipolar disorders, part III : maintenance treat-ment. World Journal of Biological Psychiatry 2004; 5: 120 –135 . DOI: https://doi.org/10.1080/15622970410029924
• 54 Miklowitz, DJ. Adjuntive psyghotherapy for bipolar disorder: state of the evidence. Am J Psychiatry 2008; 165: 1408-1419. DOI: https://doi.org/10.1176/appi.ajp.2008.08040488
• 55 Perlick DA, Miklowitz DJ, Lopez N, Chou J, Kalvin C, Adzhiashvili V, Aronson A. Family-focused treatment for caregivers of patients with bipolar disorder. Bipol Disord 2010; 12: 627-637. DOI: https://doi.org/10.1111/j.1399-5618.2010.00852.x
• 56 Reinares M, Colom F, Rosa AR, Bonnin CM, Fran-co C, Solé B, Kapczinski F, Vieta E. The impact of sta-ging bipolar disorder on treatment outcome of family psychoeducation. J Affect Disord 2010; 123: 81-86. DOI: https://doi.org/10.1016/j.jad.2009.09.009
• 57 Costa RT, Cheniaux E, Rosaes PAL, Carvalho MR, Freire RCR, Versiani M, Rangé BP, Nardi AE. The effec-tiveness of cognitive behavioral group therapy in tre-ating bipolar disorder: a randomized controlled study. Revista Brasileira de Psiquiatria 2010. DOI: https://doi.org/10.1590/S1516-44462011005000008
• 58 Isasi, AG, Echeburúa E, Liminana JM, González--Pinto, A. How effective is a psychological intervention program for patients with refractory bipolar disorder? A randomized controlled trial. J Affect Disord 2010; 126 : 8 0 - 87. DOI: https://doi.org/10.1016/j.jad.2010.03.026
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2011 Gisele Vasconcelos Serpa Dantas, Fabiana Nery Fernandes, Ângela Marisa de Aquino Miranda-Scippa
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria permite que o (s) autor (es) mantenha(m) seus direitos autorais sem restrições. Atribuição-NãoComercial 4.0 Internacional (CC BY-NC 4.0) - Debates em Psiquiatria é regida pela licença CC-BY-NC
